What is Liraglutide?
Liraglutide is an FDA-approved GLP-1 receptor agonist available as Victoza (diabetes) and Saxenda (weight management). It was the first GLP-1 agonist approved specifically for chronic weight management. While newer agents show greater efficacy, liraglutide paved the way for the GLP-1 revolution.
Key Benefits & Mechanisms
FDA-approved for weight management
Proven glycemic control
Cardiovascular risk reduction (LEADER trial)
Well-established safety profile
Appetite suppression
Improved metabolic biomarkers
Daily dosing allows precise titration
Research Summary
Liraglutide has extensive Phase III evidence (SCALE, LEADER programs). FDA-approved with a robust long-term safety database. LEADER trial demonstrated cardiovascular benefit. First-generation GLP-1 for weight loss with well-characterized efficacy (5-8% body weight reduction).